Novartis AG (VTX:NOVN) PT Set at CHF 94 by Sanford C. Bernstein

Novartis AG (VTX:NOVN) has been given a CHF 94 price objective by equities researchers at Sanford C. Bernstein in a research report issued to clients and investors on Tuesday, July 18th. The firm currently has a “buy” rating on the stock.

A number of other research analysts also recently issued reports on the company. J P Morgan Chase & Co set a CHF 70 price objective on Novartis AG and gave the stock a “neutral” rating in a report on Saturday, May 20th. Goldman Sachs Group, Inc. (The) set a CHF 80 price objective on Novartis AG and gave the stock a “neutral” rating in a report on Saturday, May 20th. Jefferies Group LLC set a CHF 100 price objective on Novartis AG and gave the stock a “buy” rating in a report on Saturday, May 20th. Morgan Stanley set a CHF 75 price objective on Novartis AG and gave the stock a “sell” rating in a report on Saturday, May 20th. Finally, Barclays PLC set a CHF 65 price objective on Novartis AG and gave the stock a “sell” rating in a report on Friday, June 2nd. One research analyst has rated the stock with a sell rating, seven have given a hold rating and seven have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average price target of CHF 84.60.

Shares of Novartis AG (NOVN) traded up 0.49% during midday trading on Tuesday, hitting CHK 82.45. The company had a trading volume of 2,716,458 shares. Novartis AG has a 12-month low of CHK 67.40 and a 12-month high of CHK 84.35. The firm’s 50-day moving average is CHK 81.03 and its 200-day moving average is CHK 77.32. The firm has a market capitalization of CHK 193.17 billion and a P/E ratio of 30.10.

TRADEMARK VIOLATION WARNING: “Novartis AG (VTX:NOVN) PT Set at CHF 94 by Sanford C. Bernstein” was published by BBNS and is the property of of BBNS. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/markets/novartis-ag-vtxnovn-given-a-chf-94-price-target-at-sanford-c-bernstein-updated-updated/1251158.html.

About Novartis AG

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Analyst Recommendations for Novartis AG (VTX:NOVN)

Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with our FREE daily email newsletter.

 


Latest News

Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns
Darren Daulton Former Catcher with Phillies Dies
Darren Daulton Former Catcher with Phillies Dies


Leave a Reply

 
© 2006-2017 BBNS.